(Q44097181)

29 November 2017

0 references

Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward? (English)

1 reference

29 November 2017

1 reference

Stefano Lazzeri

1

1 reference

29 November 2017

Marco Nardi

series ordinal

2

1 reference

29 November 2017

Guido Bocci

series ordinal

3

1 reference

29 November 2017

publication date

1 August 2013

1 reference

29 November 2017

1 reference

29 November 2017

volume

14

1 reference

29 November 2017

issue

11

1 reference

29 November 2017

page(s)

1239-1242

1 reference

Ranibizumab for neovascular age-related macular degeneration

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

The possible role of chemotherapy in antiangiogenic drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.100

21 January 2018

Identifiers

DOI

10.2217/PGS.13.100

1 reference

release_puerrqhp4fgjnjdccx3m6carim

29 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/puerrqhp4fgjnjdccx3m6carim

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference